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Over the past several years, considerable success for the
treatment of lysosomal-storage disorders has been gained
through the use of enzyme-replacement therapy (ERT).
One of the major advances that led to the ﬁrst available
therapy, for Gaucher disease, was efﬁcient targeting of
recombinant glucocerebrosidase to macrophages via the
mannose receptor. This is achieved by the removal from
the enzyme of terminal sugars in order to exposemannosyl
residues. Most of the currently used recombinant lyso-
somal enzymes have mannosyl andmannose-6-phosphate
residues that use the corresponding receptors for uptake
from the plasma. A key remaining issue with ERT for lyso-
somal-storage disorders is the fact that the therapeutic
enzyme cannot cross the blood-brain barrier to ameliorate
the central nervous system effects associated with some of
these disorders. In the hope that it might increase delivery
across the blood-brain barrier, Grubb et al. attempted to
increase the bioavailability of recombinant enzyme in
a mouse model of mucopolysaccharidosis type VII (MPS
VII) through avoidance of uptake by the mannose or man-
nose-6-phosphate receptors. They modiﬁed the relevant
enzyme, b-glucoronidase (GUS), by chemical inactivation
of terminal sugars and showed that this increased the
plasma half-life in treated mice from 11.7 min to 18.5 hr.
In several tissues, higher levels of enzyme were achieved
in mice given the modiﬁed GUS compared to the unmod-
iﬁed enzyme. Most notable was the brain, in which en-
zyme levels equivalent to almost 8% of the wild-type level
were achieved. In hippocampal neurons of MPS VII mice
treated with modiﬁed GUS, lysosomal accumulations
were virtually eliminated, whereas the accumulations were
unaffected by treatments with the unmodiﬁed enzyme.
It is as yet unclear how the modiﬁed GUS is getting across
the blood-brain barrier, but these results suggest that impro-
vement of the neurological manifestations of lysosomal-
storage disorders may be within our grasp.
J.H. Grubb et al. PNAS 105, 2616-2621, 10.1073/
pnas.0712147105.
Shades Of White
Everybody seems to be a geneticist nowadays. Any pheno-
type that has a whiff of heritability is a target for a geneticassociation study. But experience has shown that this rush
to ﬁnd genetic variation that contributes to complex traits
has resulted in many false-positive associations. One
source of these false-positive results is population stratiﬁca-
tion, or the presence of allele frequency differences be-
tween two groups that is based on differences in popula-
tion history. To limit false associations due to population
stratiﬁcation, researchers often require that all individuals
participating in their study self-identify themselves as
belonging to a particular group, such as ‘‘white’’ or ‘‘African
American,’’ members of which would presumably share
a similar ancestral background. Research over the past
couple of years has shown that distinguishing samples in
this fashion does not fully avoid population stratiﬁcation
and that, even within white European samples, population
structure exists. Ancestry informative markers (AIMs) are
genetic markers that are selected to ﬁnd population struc-
ture so that it can be properly controlled. Sets of AIMs
have previously been proposed for use in European pop-
ulations, but they have tended to be very large sets of
markers that would be appropriate for use in whole-ge-
nome studies, rather than replication studies that require
limited genotyping. Tian et al. and Price et al. have each
used large collections of European American samples to
demonstrate that the population structure observed in Eu-
rope is also found in this group. As previously noted for
European samples, there is a north-south cline of ancestry
in Europe and a less distinct east-west cline, and the Ashke-
nazi Jewish population separates out as a distinct group,
regardless of geographic location. Each group proposes
small sets of AIMs that lack the high genotyping burden
of previously proposed marker sets but can still distinguish
European population substructure and provide appropri-
ate control to avoid spurious genetic associations. An ac-
companying Perspective article by the two research groups
suggests which AIM sets might be appropriate in different
situations.
A.L. Price et al. (2008). PLoS Genet. 4, e236, 10.1371/
journal.pgen.0030236; C. Tian et al. (2008). PLoS Genetics
4, e4, 10.1371/journal.pgen.0040004.
The Future Is Now
Most of us have heard about or even spouted off on the
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the idea that, in the future, doctors will genotype individ-
uals for a series of markers that can predict drug efﬁcacy as
well as adverse events. Over the past few months, this
promise is becoming reality. This summer, the anticoagu-
lant warfarin became the ﬁrst widely prescribed drug to in-
clude genetic testing in its label information because of the
wealth of data that variation in CYP2C9 and in VKORC1
inﬂuences the response to warfarin. Now Mallal et al.
have provided crucial data that support the use of prospec-
tive genetic screening prior to prescription of the widely
used antiretroviral drug abacavir. Approximately 5% of
people who receive abacavir have a hypersensitivity reac-
tion to the drug, and this can even be life-threatening.
The HLA-B*5701 allele has been reported in several studies
to be highly associated with this reaction. As part of the
PREDICT-1 study, Mallal et al. did a double-blind, prospec-
tive, randomized study to determine the effectiveness of
prospective genotyping for HLA-B*5701 in reducing hy-
persensitivity reactions to abacavir. One difﬁculty with
studies of the hypersensitivity reaction is that it tends to
be overdiagnosed—even individuals not taking abacavir
have been diagnosed with an abacavir-hypersensitivity re-
action in some studies. To address this issue, the authors
used a skin-patch test to immunologically conﬁrm hyper-
sensitivity reactions in their sample. The authors found
that screening for HLA-B*5701 and withholding abacavir
from this subset of the sample completely eliminated
immunologically conﬁrmed hypersensitivity reactions.
Although nearly 39% of HLA-B*5701 carriers in the
nonscreened group tolerated abacavir for the observation
period, prescreening for this allele identiﬁes a group of
individuals at the greatest risk for a reaction to abacavir.
Ordering this pharmacogenetic test prior to prescription
of abacavir may be standard of care in the near future.
S. Mallal et al. (2008). NEJM 358, 568–579.
About Face
In Treacher Collins syndrome (TCS), haploinsufﬁciency for
TCOF1, which encodes Treacle, causes deﬁciencies in mi-
grating neural crest cells that ultimately cause craniofacial
defects. Because TCOF1 haploinsufﬁciency causes insufﬁ-
cient ribosome biogenesis, previous work had proposed
that this ribosome deﬁciency directly caused neuroepithe-
lial apoptosis and the resulting lack of appropriate neural
crest cell production. Jones et al. attempted to understand
the pathogenic process of TCS more clearly by using a
mouse model for the disease and found that p53, rather
than ribosome, deﬁciencies are the key to TCS. Microarrays
of embryonic mice revealed several p53-responsive genes
that were upregulated in Tcof1þ/ embryos, compared to
wild-type, a result that led the authors to discover higher538 The American Journal of Human Genetics 82, 537–538, Marchp53 protein levels in the Tcof1þ/ embryos. Working with
the hypothesis that Tcof1þ/ causes p53 activation of
downstream targets, they treated pregnant mice with the
p53 inhibitor piﬁthrin-a and found that it brought neuro-
epithelial apoptosis in Tcof1þ/ embryos to levels more
closely resembling those of wild-type embryos. Provided
it was given long enough during the pregnancy, this treat-
ment also rescued the craniofacial defects in Tcof1þ/ pups.
Genetic reductions in p53 had similar effects. Although
the TCS-like phenotype was rescued by manipulations of
p53, the production of mature ribosomes was unaffected,
excluding this Tcof1þ/-associated feature as directly caus-
ing the craniofacial anomalies associated with TCS and
incriminating p53 and its targets in TCS pathogenesis.
Although p53 manipulation in mice rescued the obvious
defects in Tcof1þ/ mice, these manipulations were per-
formed very early in embryogenesis, making it difﬁcult to
translate these ﬁndings directly into treatment of humans.
Now that p53 and its targets are the culprits in this disease,
this work does, however, provide us with many new
avenues of therapy to explore.
N.C. Jones et al. (2008) Nat. Med. 14, 125–133.
Recombination See-Saw
The recombination rate varies across chromosomes,
among individuals, and between the sexes. This process
must be tightly regulated because errors can have severe
consequences, including chromosomal rearrangements
and nondisjunction. But what factors are involved? Kong
et al. approached this question through a genome-wide
association study using more than 3000 individuals for
whom they had recombination-rate estimates. In males,
three SNPs in the same area of chromosome 4p16.3 were
the only ones that achieved genome-wide signiﬁcance,
and the same three SNPs were associated with recombina-
tion rates in females. However, the associations with these
SNPs were in opposite directions in the two sexes; the hap-
lotype associated with a decrease in the genome-wide re-
combination rate in males is associated with an increased
recombination rate in females. Evolutionarily, this creates
a see-saw effect whereby when the female recombination
rate is up, the male recombination rate goes down and
the overall average recombination rate in the population
stays fairly similar. Two genes are found in the block of
linkage disequilibrium represented by the associated hap-
lotype. RNF212, a putative ortholog of a gene involved in
recombination in C. elegans, is believed to be the relevant
gene for the association, but functional studies have not
yet been performed.
A. Kong et al. (2008) Science. Published online January 31,
2008. 10.1126/science.1152422.2008
